Search - tctmd.com

Displaying 541 - 560 of 1054

Sort: Relevancy | Date

Many PCI Patients Treated in China Have No Angina Symptoms

News Daily News

Many PCI Patients Treated in China Have No Angina Symptoms

December 20, 2018

Rising CVD Threatens Middle East and North Africa

News Conference News WCC 2018

Rising CVD Threatens Middle East and North Africa

December 13, 2018

More Registry Data Show No Survival Advantage for Impella in Acute MI With Cardiogenic Shock

News Daily News

More Registry Data Show No Survival Advantage for Impella in Acute MI With Cardiogenic Shock

December 11, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

November 30, 2018

Treating to New Blood Pressure Goals Could Prevent Millions of CVD Events

News Daily News

Treating to New Blood Pressure Goals Could Prevent Millions of CVD Events

November 21, 2018

TiCAB: Ticagrelor No Help for Preventing Graft Failure Post-CABG

News Conference News AHA 2018

TiCAB: Ticagrelor No Help for Preventing Graft Failure Post-CABG

November 13, 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

Study Lays Groundwork for Pivotal Trial of Impella CP for LV Unloading Before PCI

News Conference News AHA 2018

Study Lays Groundwork for Pivotal Trial of Impella CP for LV Unloading Before PCI

November 11, 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

Race May Be a Proxy for Many Disparities in CVD Treatment, Outcomes

News Daily News

Race May Be a Proxy for Many Disparities in CVD Treatment, Outcomes

Yael L. Maxwell

November 07, 2018

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

News Daily News

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Michael O'Riordan

November 06, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

News Daily News

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

October 31, 2018

TCTMD’s Top 10 Most Popular Stories for October 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

October 31, 2018

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

News Daily News

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

October 12, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

PREPARE-CALC Shows Benefits of Rotational Atherectomy

News Conference News

PREPARE-CALC Shows Benefits of Rotational Atherectomy

TCT Daily Staff

October 01, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

September 24, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.